Research of our group mainly relies on third-party funding. Over the last 17 years in
total 9.745 million Euros have been spent. The table and diagram below show the annually
spent funds, subdivided into funding sources.
| Funding agency |
Title |
Funding in Euro |
| DFG |
Structural studies of Shigella-specific Pathogenicity Factors as a
Prerequisite for Rational Drug Design
|
189,750 |
| DFG |
Understanding the Binding Characteristics of Aldose Reductase
|
113,250 |
| DFG |
Structure-based Design, Synthesis and Crystallographic
Characterisation of Aspartyl protease Inhibitors: Target proteins
for HIV- and Malaria-infection
|
132,550 |
| DFG - FO 806 |
Cross-correlation of Protein Binding Pockets to detect related
Binding Epitopes, unexpected Cross-reactivity and Functional
Relationships
|
216,000 |
| DFG |
Interfering with Intracellular Protein-protein Interactions -
Probing Protein Functions with Small Molecules, Perturbance of
Enzyme Function by Blocking Dimer Interface Formation: Novel Route
to Specific Antibiotics
|
289,100 |
| CCDC |
Development of a Scoring Function |
28,402 |
| CCDC |
Studentship on Cambridge Structural Database – Knowledge-based Hot
Spot Analysis
|
106,812 |
| Bayer Schering |
From Targets to Novel Drugs |
50,000 |
| Sanofi |
Comparison of Binding Pocket using Cavbase to Analyse and Correlate
Proteins across Protein Families and Design of Focused Libraries for
de novo Design
|
111,000 |
| Beiersdorf |
Design of Inhibitors for humane Tyrosinase by Molecular Modeling
and Crystallography
|
126,000 |
| BMBF |
Fragmentscreening "FragScreen" BioChance Plus, New methods
for Experimental and Computational Fragment-based Drug Design
|
910,876 |
| BMBF Zedira |
Development of Factor XIIIa - Inhibitors to Prevent Thrombosis
|
100,000 |
| LOEWE Synmikro |
Data Mining Methoden zur graphbasierten Analyse von Proteinstrukturdaten,
Protein-Ligand & Protein-Protein Interaktionen
|
132,300 |
| LOEWE Synmikro |
Development of novel bioinformatics methods for the prediction of
protein function and interactions. Experimental validation
|
168,000 |
| ERC AG |
Chemogenomic profiling of drug-protein binding by shape,
enthalpy/entropy and interaction kinetics
|
1,754,615 |
| BMBF FKZ |
Aufbau einer "Beamline zum direkten Fragmentscreening" an
Proteinkristallen zur Leitstrukturentwicklung
|
640,609 |
| DFG |
17beta-Hydroxysteroid Dehydrogenase Typ 14: Enzymstruktur-basierte
Entwicklung von potenten und selektiven Inhibitoren mit Hilfe von
Kristallisation und Enzymcharakterisierung
|
156,500 |
| LOEWE SynChemBio |
Innovative Synthesechemie für die selektive Modulation
biologischer Prozesse - Schwerpunkt S-07
|
140,000 |
| DFG |
Durchführung einer Tagung FiMC
|
25,000 |
| BMBF Zedira |
Entwicklung von Faktor XIIIa - Inhibitoren zur Thromboprophylaxe
- Stufe 2
|
59,901 |
| GA-Nr. 675555 |
EU-Projekt AEGIS (Accelerated Early staGe dIScovery – EU-Horizon 2020 “Marie Skłodowska-Curie Innovative Training Networks”-Maßnahme
|
498,432 |
| BMBF Frag4Lead FKZ 05K16RM1 |
Hochdurchsatz-Kristallographie am Synchrotron: von Fragmenten zu Leitstrukturen Förderzeitraum: 01.07.2016 – 30.06.2019
|
925,158 |
| DFG KL 1204/23-1 |
Entwicklung niedermolekularer Inhibitoren und Stabilisatoren der Dimerisierung von tRNA-Guanin Transglykosylase
|
325,950 |
| BMBF 03EGSHE147 |
EXIST-Gründerstipendium: smart-soak – Dienstleistungen in der Wirkstoffentwicklung
|
156,600 |
| LOEWE DRUID |
Wirkstoffentwicklungen zum Bekämpfen der Virulenzentwicklung des Ruhr-Erregers Shigella
|
230,400 |
| Total |
|
7,587,205 |
